Kornimate/medical-research-clean huggingface dataset:
nsaid vs. narcotics

Conditions: Multimodal Analgesia; Nonsteroidal Anti-inflammatory Drugs

Summary: this will be a single-center, prospective observational study. the study will compare post-operative pain scores and narcotic consumption between two groups of patients - one cohort will receive ibuprofen (motrin) and percocet (to be used as needed) while the other cohort will receive only percocet. both pain management options are considered to be standard of care. the primary objective of the study is to compare patients' reported pain and narcotic use following meniscectomy, and determine if nsaids can provide adequate pain relief.


Eligibility criteria:
inclusion criteria: * must be at least 18 years of age * asa class i-ii * patients scheduled for meniscectomy exclusion criteria: * contraindication to ibuprofen or oxycodone/acetaminophen (e.g. hypersensitivity, history of gi or bleeding disorder) * legally incompetent or mentally impaired (e.g. minors, alzheimer's subjects, dementia, etc.) * younger than 18 years of age or older than 65 * any patient considered a vulnerable subject * patients on pain medication prior to surgery

Keywords: analgesic efficacy knee arthroplasty opioid consumption pain medicine narcotics multimodal analgesia
long-term outcomes of anti-viral therapies in patients with chronic viral hepatitis b

Conditions: Chronic Hepatitis b

Summary: this is a multicenter, prospective, real-world study, recruiting patients with chronic hepatitis b under anti-viral treatment. the recruited participants will receive peginterferon alpha based regimen or nucleos(t)ide alone. the primary objective of this study is to compare the long-term outcomes (including hepatocellular carcinoma, decompensated cirrhosis, etc）of different anti-viral therapies. the secondary objective of this study is to compare the serological response rates of different anti-viral therapies, evaluate the predictive value of hbv-related laboratory testings and describe the kinetics of them results during antiviral treatment. the follow-up time course of this study will be 5 years.

the patients will be allocated into two cohorts based on the anti-viral treatment decided by their doctors. if they are going to take peginterferon alpha based regimen, they will be allocated in interferon cohort. if they are going to take nucleos(t)ide alone, they will be allocated in nucleos(t)ide cohort. the follow-up plan will be made by their doctors according to their conditions. no extra intervention or examination will be given in this study. the primary outcome is end-stage liver diseases including hepatocellular carcinoma and decompensated cirrhosis, and the rate of hepatocellular carcinoma and decompensated cirrhosis will be measure at 1 year，2 years，3 years, 4 years and 5 years from baseline. secondary events including hbsag loss, hbeag conversion, fibrosis progression and fibrosis, which will be measured at 24 weeks, 48 weeks, 72 weeks, 96 weeks, 120 weeks, 144 weeks, 168 weeks, 192 weeks, 216 weeks, 240 weeks from baseline, respectively. results of laboratory testings will be recorded at each follow-up visit. the primary objective of this study is to compare the long-term outcomes (including hepatocellular carcinoma, decompensated cirrhosis, etc）of different anti-viral therapies. the secondary objective of this study is to compare the serological response rates of different anti-viral therapies, evaluate the predictive value of hbv-related laboratory testings and describe the kinetics of them results during antiviral treatment.

Eligibility criteria:
inclusion criteria: * male and female patients with age ≥18; subjects who are over 70 years of age must be in generally stable health conditions. * there should be evidences that hbsag has been positive for more than 6 months or hbv-related histological changes. * planned to receive or already receiving anti-viral treatment with nucleos(t)ide including entecavir, tenofovir, and tenofoviralafenamide. or planned to receive peginterferon alpha 2b, either treated or treatment-naive. * agree to participate in the study and sign the patient informed consent form. exclusion criteria: * currently treatment-related participating clinical trials.
nab-paclitaxel as second-line therapy in locally advanced or metastatic squamous lung cancer

Conditions: Squamous Cell Carcinoma of Lung

Summary: the purpose of this study is to determine the efficacy of nab-paclitaxel monotherapy in previously treated advanced or metastatic squamous lung cancer.

nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel, solvent-free, albumin-bound nanoparticle form of paclitaxel designed to avoid problems associated with solvents used in taxol. and albumin-bound paclitaxel was characterized with high tolerated doses with greater efficacy, and with greater concentration in tumor tissue compared with normal tissues. a multicenter randomized controled trial (coded as ca031) showed that nab-paclitaxel in combination with carboplatin had higher response rate than traditional paclitaxel plus carboplatin, especially in squamous lung cancer. this is a single center, non-randomized, open-label phase ii clinical study to investigate the efficacy and tolerability of nab-paclitaxel monotherapy in previously treated advanced or metastatic squamous lung cancer after failure of platinum-based doublet therapy.

Eligibility criteria:
inclusion criteria: 1. signed informed-consent form; 2. age no less than 18 years; 3. histologically confirmed locally advanced or metastatic squamous lung cancer; 4. eastern cooperative oncology group (ecog) 0-2 with life expectation of no less than 12 weeks; 5. recist measurable lesions; 6. disease progression after failure of platinum-based doublet therapy; 7. adequate liver/renal/bone marrow function; 8. human chorionic gonadotropin (hcg) test negative for female with contraception measures until 3 months after study end; 9. compliance, and can be followed up regularly. exclusion criteria: 1. pregnant or breast-feeding female, or not willing to take contraception measures during study; 2. radiotherapy within 30 days, systematic therapy within 21 days; 3. serious infection requiring antibiotics intervention during recruitment; 4. allergic to study drug; 5. require concurrent biological target therapy; 6. more than grade 1 neuropathy; 7. uncontrolled brain metastasis or mental illness; 8. congestive heart failure, uncontrolled cardiac arrhythmia, etc; 9. other malignancy within 5 years; 10. can't be followed up or obey protocol; 11. ineligible by the judge of the investigator.

Keywords: nanoparticle albumin-bound paclitaxel squamous cell carcinoma of lung
creatine augmentation treatment in major depressive disorder subjects

Conditions: Major Depressive Disorder

Summary: given 1) the established safety with short-term or long-term supplementation of cr, 2) its potential usefulness in improving brain energy metabolism, 3) the reported abnormality in brain energy metabolism in mdd subjects, and 4) plausible association between depression and inflammatory mediators, we hypothesize that oral cr augmentation will help reduce symptoms in mdd patients as well as normalize a deficit in brain energy metabolism and that improvement of mdd and brain energy metabolism will be correlated with inflammatory mediators changes. in this study, we plan to conduct an randomized, double-blind, placebo-controlled augmentation study with creatine in addition to escitalopram. we will assess the efficacy and safety of the cr augmentation and evaluate changes relevant to brain energy metabolism and inflammatory mediators.


Eligibility criteria:
inclusion criteria: * 19-65 year-old male or female * major depressive disorder diagnosed by scid-iv * hamilton depression rating scale score \>= 16 at screening * written informed consent exclusion criteria: * suicidal idea that needs hospitalization * any other axis i psychiatric disorder * neurologic disease (eg., epilepsy, infarct, multiple sclerosis, brain tumor) * iq below 80 * inflammatory disease including autoimmune disease * taking anti-inflammatory medication * serious physical disease * substance abuse or dependence history in recent 6 months * pregnant or having plan to be pregnant

Keywords: creatine augmentation major depressive disorder efficacy brain energy metabolism
determination of the predictors of nocturnal desaturation in postpartum women

Conditions: Sleep Disordered Breathing; Nocturnal Oxygen Desaturation; Upper Airway Edema

Summary: the primary aim of the study is to evaluate the effect of the method of delivery (vaginal delivery vs. cesarean section) on oxygen saturation in the first postpartum night. the investigators hypothesize that nocturnal desaturation occurs more frequently in cesarean section compared with vaginal delivery, expressed as either the duration of spo2 below 90% or the oxygen desaturation index (odi). the odi is defined as number of oxygen desaturations by at least 3 % per hour. furthermore, the investigators expect a higher pulse rate and a lower mean and minimum spo2 in the cesarean section group compared with the vaginal delivery group. the secondary aim of the study is to investigate how the upper body position during sleep (45 degree elevated vs. non-elevated) affects the oxygen saturation during the first postpartum night. the investigators hypothesize that an upper body elevation to 45 degrees decreases the incidence of desaturation events, expressed as either the duration of spo2 below 90% or the odi , compared with a non-elevated body position within each delivery group (vaginal delivery or cesarean section). the third aim of the study is to identify independent predictors of nocturnal desaturation in postpartum women. to that end, the investigators will administer questionnaires and collect demographic and clinical data according to various obstructive sleep apnea screening scores, including the p-sap, stop-bang, and epworth sleepiness scale. the investigators will also ask the patient to rate the pain during the study night on a verbal numerical rating scale.

sleep-disordered breathing is common in pregnancy, persisting into the early postpartum period. postpartum airway obstruction is a main cause of anesthesia-related maternal death in north america. upper airway edema following labor and delivery may impair pharyngeal anatomy, which can lead to increased vulnerability of the airway collapse during sleep. this study evaluates whether the kind of delivery (vaginal birth versus cesarean section) has an effect on nocturnal desaturation in the first night after delivery. furthermore, the investigators examine if the upper body position during sleep has an effect on the occurrence of oxygen desaturation. in addition, the investigators evaluate if preexisting conditions, as indicated by a high p-sap or stop-bang-score increase the likelihood of nocturnal desaturation.

Eligibility criteria:
inclusion criteria: * postpartum mothers within 24 hours of delivery * age over 18 years. * admitted to the massachusetts general hospital ob service for the delivery. * interventions will be randomly assigned to the patients enrolled in this study exclusion criteria: * 1 age under 18 years
cognitive support technology for postsecondary students with traumatic brain injuries

Conditions: TBI (Traumatic Brain Injury)

Summary: this study will fill important knowledge gaps in the availability of best practices that use innovative methods to integrate the cognitive and vocational needs of students with tbi who will be transitioning from 2- and 4-year postsecondary education to employment. best practices exist from the assistive technology (at) field to help people compensate for cognitive impairments, and from the vocational rehabilitation (vr) field to enhance employment outcomes for individuals with disabilities. however, these practices have not been integrated to provide needed supports and services to improve the employment outcomes of students with tbi. the study's goal is to expand the availability of innovative practices by testing the efficacy of a technology-driven, long-term, and resource-rich individualized support program that merges assistive technology for cognition and vocational rehabilitation practices. the end products will include technology application guidelines, training and procedural manuals, and resource information that rehabilitation professionals and students with tbi can utilize to enhance technology and mentoring proficiency, academic success, self-determination, and long-term career success for students with tbi.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of tbi * enrolled in a degree program at two-year and four-year colleges or universities * live within a 60-mile radius of kent, ohio exclusion criteria: * no exclusion criteria will be applied
electrophysiological effects of nacos and avk on pulmonary veins and left atrium in paroxysmal af catheter ablation

Conditions: Atrial Fibrillation

Summary: atrial fibrillation (af) is the most common cardiac arrhythmias with a constantly growing prevalence af. the purpose of paroxysmal af processing is to control outbreaks from these pulmonary veins, medicated way (antiarrhythmic) or interventional. ablation (radiofrequency or cryotherapy) has become in this context recognized and effective treatment of af. in addition, antithrombotic treatments in this context is a major treatments for the prevention of stroke (stroke). they are most often associated with antiarrhythmic treatment to prevent recurrence of af or to slow it during a relapse. recent experimental studies have highlighted the direct electrophysiological properties of dabigatran and rivaroxaban in the pulmonary veins and the left atrium. dabigatran demonstrated in this study that it induced a prolongation of potential action in the pulmonary veins and the left atrium and it decreased the incidence of fa-induced by stimulation. conversely, rivaroxaban induces shortening of the action potential in the left atrium (untested properties in the pulmonary veins). to our knowledge, apixaban and warfarin have not been studied in this context. it is therefore possible that some of the new oral anticoagulants (nacos) or some avk (fluindione and warfarin), have direct electrophysiological effects in the pulmonary veins and on the left atrium and could influence af recurrences (with effect " antiarrhythmic-like "or rather a pro-arrhythmic effect) after ablation.a retrospective analysis conducted at the university hospital of caen on very low numbers suggest that patients on dabigatran would have less pulmonary veins connected in early ablation procedure that patients on warfarin or rivaroxaban. despite the limitations inherent in this analysis (very low numbers, retrospective analysis, unique setting and having studied his own limits), these results are consistent with the fundamental studies, and thus encourage us to pursue our hypothesis to obtain more statistical power and reliability in our measurements and results. we therefore propose the study of the electrophysiological effects of nacos (apixaban, dabigatran, rivaroxaban) and warfarin (warfarin and fluindione) on the pulmonary veins and the left atrium of patients referred for ablation of paroxysmal af (radiofrequency or cryotherapy ) the chu of caen and tours and clinic saint martin caen.


Eligibility criteria:
inclusion criteria: * all hospitalized patients for ablation of paroxysmal af * on healthy heart * sinus rhythm during the procedure * patient\> 18 years exclusion criteria: * patient \<18 years * severe mitral valve disease, * underlying heart disease * patients refusing to participate to the study

Keywords: atrial fibrillation pulmonary veins oral anticoagulant electrophysiology anticoagulant drugs
study of acamprosate in fragile x syndrome

Conditions: Fragile X Syndrome

Summary: in this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with fragile x syndrome (fxs).

each subject with fxs will receive 10 weeks of blinded treatment with acamprosate or matching placebo. after completion of the double-blind phase, all subjects will have an opportunity to receive acamprosate as part of the study procedures for 16 weeks.

Eligibility criteria:
inclusion criteria: * diagnostic confirmation of full mutation fxs * age ≥5 years and \<23 years * general good health as determined by physical exam, medical history and laboratory work up. exclusion criteria: * use of more than two psychotropic medications (medications affecting behavior). * unstable dosing of any psychotropic medication (medication affecting behavior) * problems with kidney functioning * unstable seizure disorder * change in any anti-convulsant drug dosing in the 60 days prior to study entry * prior adequate treatment trial with acamprosate as determined by the study doctor * pregnant or lactating females

Keywords: fragile x syndrome
iv iron-induced hypophosphatemia after rygb

Conditions: Hypophosphatemia; Roux-en-Y Gastric Bypass

Summary: the primary objective of the study is to compare the incidence of hypophosphatemia in rygb patients treated with intravenous (iv) single dose of iron isomaltoside (monofer®) or ferric carboxymaltose (ferinject®).


Eligibility criteria:
inclusion criteria: * patients over 18 years * signed informed consent * patients with previous rygb surgery performed \> 12 months ago * failed response to oral iron supplementation * established diagnosis of iron deficiency by ferritin \< 50 ug/l or serum ferritin ≤100ug/l and low transferrin saturation (tsat) ≤ 30% * normal phosphate blood level (0.8 - 1.45 mmol/l) before infusion * normal magnesium blood level (0.65-1.05 mmol/l) * outpatient exclusion criteria: * - patients with known hypersensitivity to iron preparation and/or anaphylaxis from any cause * patients for whom a treatment with one of the iv iron is contra-indicated (based on product summary of product characteristics) * women who are pregnant or breastfeeding * intention to become pregnant during the course of the study * renal failure, chronic kidney disease stage 3b or worse (egfr ≤ 45 ml/min/1.73m2) * patients who received iv iron infusion during the last 3 months before screening * treatment with erythropoietin or erythropoietin-stimulation agents, red blood cell transfusion within the last 3 months prior to screening * alcohol or drug abuse within the past 6 months * planned surgical procedure within the clinical trial period * surgery under general anaesthesia within the last 3 months prior to screening * hyperparathyroidism * kidney transplantation * inability to follow study procedures or give informed consent * use and inability to stop from v0 to study end, phosphate supplementation (except daily multivitamin preparation recommended after bariatric surgery; the exact amount of phosphate and iron supplementation in the daily multivitamin will be recorded) * osteoporosis drug therapy (bisphosphonates, denosumab or selective oestrogen receptor modulators). * patient who refuses to be informed of incidental discoveries that may contribute to the prevention, diagnosis, and treatment of existing or probable future illnesses.
breath analysis for evaluation of radiation exposure in lung cancer patients treated with radiation

Conditions: Lung Cancer; Non-Small Cell Lung Cancer; Small Cell Lung Cancer

Summary: patients treated with radiation therapy for lung tumors can experience inflammation after treatment. this study hopes to evaluate the use of breath analysis to evaluate changes in the composition of exhaled breath in patients undergoing radiotherapy. if changes can be detected, this may ultimately serve as biomarkers for identifying patients at highest risk for radiation-induced lung injury (radiation pneumonitis).


Eligibility criteria:
inclusion criteria: * diagnosis of any type of lung tumor * medical recommendation (independent of the study) that the patient undergo thoracic radiation therapy. radiation therapy may be either fractionated or hypofractionated (i.e. radiosurgery) * age \>= 18 years old * any gender and any ethnic background will be recruited * capable of giving written informed consent exclusion criteria: * inability of giving written informed consent * pregnancy or breast-feeding

Keywords: lung cancer non-small cell cancer (nsclc) lung cancer small cell lung cancer (sclc)
changes in bile acid homeostasis and stool habits after cholecystectomy

Conditions: Bile Acid Malabsorption; Cholelithiasis

Summary: investigate serial plasma samples of fibroblast growth factor 19 (fgf19) after oral stimulation with chenodeoxycholic acid in the same subjects before and after elective cholecystectomy

lack of fgf19 and elevated 7-alpha-hydroxy-colestenone (c4) is associated with the bile acid diarrhoea (bad), a disease with increasing estimated of prevalence. bad is occasionally triggered by cholecystectomy and fgf19 and c4 is known to be affected by cholecystectomy. the investigators are exploring if fgf19 after oral stimulation can be developed to a universal test for bad, and need to know how the proposed test is affected by cholecystectomy.

Eligibility criteria:
inclusion criteria: * planned elective cholecystectomy exclusion criteria: * small bowel resection * right sided hemicolectomy * known chronic diarrheal disease (celiac disease, lactose malabsorption, inflammatory bowel diseases, incl microscopic colitis) * pregnancy * wish for pregnancy within next three months * allergy to eggs * allergy to constituents in xenbilox (capsules with chenodeoxycholic acid) * acute cholecystitis within two months * chronic cholecystitis * cirrhosis of the liver * suspected obstructive choledocholithiasis * icterus
ombitasvir/abt-450/ritonavir and dasabuvir therapy with low dose ribavirin (rbv), full dose rbv or rbv add-on in treatment naive genotype 1a hepatitis c virus infected adults

Conditions: Chronic Hepatitis C; Hepatitis C (HCV); Hepatitis C Genotype 1a

Summary: to evaluate the effect of ribavirin on second phase plasma hepatitis c virus (hcv) ribonucleic acid (rna) decline in participants who receive ombitasvir/abt-450/ritonavir and dasabuvir with full dose ribavirin, low dose ribavirin or without ribavirin for 2 weeks in treatment-naive hcv genotype (gt) 1a-infected adults.


Eligibility criteria:
inclusion criteria: 1. screening laboratory result indicating hcv genotype 1 (gt1) a infection. 2. chronic hcv infection. 3. subjects must be non-cirrhotic. 4. subjects must be able to understand and adhere to the study visit schedule and all protocol requirements as well as voluntarily sign and date an institutional review board (irb) approved informed consent. exclusion criteria: 1. women who are pregnant or breastfeeding. 2. positive test result for hepatitis b surface antigen (hbsag) or anti-human immunodeficiency virus antibody (hiv ab) positive immunoassay. 3. clinically significant abnormalities or co-morbidities, other than hcv infection, that make the subject unsuitable for this study or treatment. 4. current enrollment in another interventional clinical study. previous use of any hcv treatments including pegylated interferon (pegifn), ribavirin, or any direct acting antiviral agent, either investigational or approved, for hcv including protease inhibitors, nucleoside or non-nucleoside polymerase inhibitors, or nonstructural viral protein 5a (ns5a) inhibitors. 5. history or solid organ transplant. 6. screening laboratory analysis that shows abnormal results.

Keywords: treatment naive hcv interferon free hepatitis c genotype 1a chronic hepatitis c hepatitis c